{"id":"https://openalex.org/W2582021609","doi":"https://doi.org/10.1182/blood.v108.11.1386.1386","title":"Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells.","display_name":"Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2582021609","doi":"https://doi.org/10.1182/blood.v108.11.1386.1386","mag":"2582021609"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.1386.1386","doi":"https://doi.org/10.1182/blood.v108.11.1386.1386","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.1386.1386","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016402296","display_name":"Seiichi Okabe","orcid":"https://orcid.org/0000-0002-2727-658X","observed_orcids":["https://orcid.org/0000-0002-2727-658X"]},"institutions":[{"id":"https://openalex.org/I158929114","display_name":"Tokyo Medical University","ror":"https://ror.org/00k5j5c86","country_code":"JP","type":"education","lineage":["https://openalex.org/I158929114"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Seiichi Okabe","raw_affiliation_strings":["First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I158929114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083522292","display_name":"Tetsuzo Tauchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I158929114","display_name":"Tokyo Medical University","ror":"https://ror.org/00k5j5c86","country_code":"JP","type":"education","lineage":["https://openalex.org/I158929114"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsuzo Tauchi","raw_affiliation_strings":["First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I158929114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038161052","display_name":"Hal E. Broxmeyer","orcid":"https://orcid.org/0000-0001-6575-0476","observed_orcids":["https://orcid.org/0000-0001-6575-0476"]},"institutions":[{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hal E. Broxmeyer","raw_affiliation_strings":["Department of Microbiology and Immunology, and The Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Immunology, and The Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I4388446366","https://openalex.org/I4394709130"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053689963","display_name":"Kazuma Ohyashiki","orcid":"https://orcid.org/0000-0003-0845-5758","observed_orcids":["https://orcid.org/0000-0003-0845-5758"]},"institutions":[{"id":"https://openalex.org/I158929114","display_name":"Tokyo Medical University","ror":"https://ror.org/00k5j5c86","country_code":"JP","type":"education","lineage":["https://openalex.org/I158929114"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuma Ohyashiki","raw_affiliation_strings":["First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I158929114"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.38075543,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"108","issue":"11","first_page":"1386","last_page":"1386"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib-resistance","display_name":"dasatinib resistance","score":0.906000018119812},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":1.0},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9829999804496765},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.8500000238418579},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9139999747276306},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.7680000066757202},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8700000047683716},{"id":"https://openalex.org/keywords/kinase-domain-mutations","display_name":"kinase domain mutations","score":0.7440000176429749},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7770000100135803},{"id":"https://openalex.org/keywords/src-kinase","display_name":"Src kinase","score":0.41999998688697815},{"id":"https://openalex.org/keywords/c-abl","display_name":"c-Abl","score":0.875},{"id":"https://openalex.org/keywords/k562-cells","display_name":"K562 cells","score":0.7319999933242798},{"id":"https://openalex.org/keywords/tf-1-cells","display_name":"TF-1 cells","score":0.9390000104904175},{"id":"https://openalex.org/keywords/drug-resistance-mechanisms","display_name":"drug resistance mechanisms","score":0.6769999861717224}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9377460479736328},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8851101398468018},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.7983845472335815},{"id":"https://openalex.org/C171122931","wikidata":"https://www.wikidata.org/wiki/Q6324626","display_name":"K562 cells","level":3,"score":0.6390042304992676},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6100208759307861},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.6010679006576538},{"id":"https://openalex.org/C125418893","wikidata":"https://www.wikidata.org/wiki/Q587961","display_name":"ABL","level":4,"score":0.5874663591384888},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5369097590446472},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5324085354804993},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4401634931564331},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4069957137107849},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3527074158191681},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21625551581382751},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.20556801557540894},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07639452815055847},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.07211002707481384}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.1386.1386","doi":"https://doi.org/10.1182/blood.v108.11.1386.1386","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.1386.1386","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2578703009","https://openalex.org/W2129503499","https://openalex.org/W2333888998","https://openalex.org/W2593539765","https://openalex.org/W2063933529","https://openalex.org/W2024021544","https://openalex.org/W2015920117","https://openalex.org/W2244675803","https://openalex.org/W200163820","https://openalex.org/W2549375654"],"abstract_inverted_index":{"Abstract":[0],"The":[1,72,406,468],"selective":[2],"tyrosine":[3],"kinase":[4,41,280,375],"inhibitor,":[5,75],"imatinib":[6,20,31,49,62,98,114,122,165,205,241,296],"has":[7,34],"shown":[8],"remarkable":[9],"clinical":[10,108],"activity":[11,90],"in":[12,39,64,97,106,110,188,278,281,293,368,382,402,411,425,475],"patients":[13,65,112],"with":[14,66,113,139,304],"chronic":[15],"myelogenous":[16],"leukemia":[17],"(CML),":[18],"however,":[19],"does":[21],"not":[22,124],"completely":[23],"eradicate":[24],"BCR/ABL-expressing":[25],"cells,":[26,351],"and":[27,50,85,121,149,153,160,164,170,185,199,202,210,226,233,249,264,297,309,316,356,366,377,398,446,450,470,487,496],"cells":[28,148,163,187,236,252,340,445],"resistant":[29,156,166,215,239,255,283,339,413],"to":[30,53,60,119,240,256,295,441,485],"develop.":[32],"It":[33],"been":[35],"reported":[36],"that":[37,177,287,337,389,458,498],"mutations":[38],"the":[40,89,140,214,265,300,321,360,444,459,481],"domain":[42],"(KD)":[43],"of":[44,48,70,82,91,182,193,204,219,302,345,418,432,437,443,466,483,493,503],"BCR/ABL":[45,74,133,141,224,231,262,288,349],"impairs":[46],"binding":[47],"causes":[51],"resistance":[52,63,99,118,294,484,495],"it.":[54],"So,":[55],"additional":[56],"therapy":[57],"is":[58,102,291,364],"necessary":[59],"overcome":[61],"an":[67],"acute":[68],"form":[69],"CML.":[71],"novel":[73],"dasatinib":[76,120,155,178,194,220,257,338,412,433,486,494],"(BMS-354825),":[77],"which":[78,136],"A":[79],"dual":[80],"inhibitor":[81],"both":[83],"Src":[84],"Abl":[86,279],"kinases,":[87,391],"suppresses":[88],"these":[92,282],"kinases":[93],"at":[94],"subnanomolar":[95],"concentrations":[96],"cells.":[100,173,371,385,405,428],"Dasatinib":[101],"presently":[103],"being":[104],"evaluated":[105],"a":[107],"trial":[109],"CML":[111],"resistance,":[115],"but":[116],"drug":[117,317],"are":[123],"fully":[125],"evaluated.":[126],"In":[127,213,347,358],"this":[128,476,499],"study,":[129],"we":[130,319],"used":[131],"TF-1":[132,147,157,167,183,230,246,348],"cell":[134,151,216,284,414],"lines,":[135,217],"were":[137,237,253,379,400],"transfected":[138],"gene,":[142],"as":[143,145,394,396],"well":[144,395],"parental":[146],"K562":[150,161,171,186,234,250,272,369,383,403,426,438],"lines":[152,285],"established":[154],"BCR-ABL":[158,168,184,247],"BMS-R":[159,162,232,235,350,370,384,427,439],"IM-R":[169,172,248,251,404],"We":[174,335,386,455],"show":[175],"here":[176],"potently":[179],"induced":[180],"apoptosis":[181,442],"72":[189],"hours":[190],"treatment.":[191],"IC50":[192,203,218],"was":[195,206,221,267,275,354,409,423,462],"0.75nM":[196],"(TF-1":[197,208,223,261],"BCR/ABL)":[198,209],"1nM":[200],"(K562)":[201],"500nM":[207],"750nM":[211],"(K562).":[212],"15\u03bcM":[222],"BMS-R)":[225],"25\u03bcM":[227],"(K562":[228],"BMS-R).":[229],"also":[238,254,380,387,456],"(IC50:":[242,258],"more":[243,268],"than":[244,269],"10\u03bcM).":[245],"7.5":[259],"nM":[260],"IM-R)":[263],"value":[266],"10nM":[270],"for":[271],"IM-R).":[273],"There":[274],"no":[276],"mutation":[277],"suggesting":[286],"mutation-independent":[289],"mechanism":[290,482],"involved":[292],"dasatinib.":[298,467],"Because":[299],"correlation":[301],"parameters":[303],"defined":[305],"protein":[306,310,322,343,353,374,471],"expression":[307,323,469],"patterns":[308],"signatures":[311,473],"would":[312],"predict":[313],"disease":[314],"progression":[315],"resistant,":[318],"investigated":[320],"pattern":[324],"by":[325],"using":[326],"antibody":[327],"microarray":[328],"system":[329],"(Antibody":[330],"Microarray:":[331],"Lab":[332],"Vision":[333],"Corporation).":[334],"found":[336,388,457],"had":[341],"reduced":[342,424],"levels":[344],"BCR/ABL.":[346],"Zap-70":[352],"increased":[355,365,463],"activated.":[357],"contrast,":[359],"src":[361,390],"kinase,":[362],"lck,":[363],"activated":[367,381,401,447],"Moreover,":[372],"mitogen-activated":[373],"(MAPK)":[376],"Akt":[378,399],"especially":[392],"Lyn,":[393],"MAPK":[397],"phosphatase":[407,460],"SHP-2":[408],"decreased":[410],"lines.":[415],"Signal-transducing":[416],"activators":[417],"transcription":[419],"5":[420],"(STAT5)":[421],"phosphorylation":[422],"24":[429],"hour":[430],"removal":[431,465],"from":[434],"culture":[435],"medium":[436],"led":[440],"caspase":[448],"3":[449],"poly":[451],"(ADP-ribose)":[452],"polymerase":[453],"(PARP).":[454],"SHP-1":[461],"after":[464],"activation":[472],"identified":[474],"study":[477,490],"provide":[478],"insight":[479],"into":[480],"imatinib.":[488],"Our":[489],"demonstrates":[491],"development":[492],"suggests":[497],"information":[500],"may":[501],"be":[502],"therapeutic":[504],"relevance.":[505]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-03T00:00:00"}